systemic-preparative regimens as areas in which 
modifications must be made in order to achieve increased 
number of stable remissions. 
3.0 BACKGROUND DRUG INFORMATION (See Appendices C for 
chemotherapy (cyclophosphamide) and Appendix G for the 
LNL-6 and GINa viruses) . 
4.0 PATIENT ELIGIBILITY 
4.1 CLL patients who have progressed following 
conventional dose therapy, who are less than 60 years 
of age and have a life expectancy of 1 year, and are ' 
ineligible for allografting. 
4.2 Prior treatment does not disqualify a patient from 
eligibility. 
4.3 Patients must have a performance <3 on Zubrod scale 
(Appendix Al) , a creatinine level less than 1.6 mg%, 
acceptable cardiac condition (class I or II; Appendix 
2), normal liver functions with bilirubin less than 2 
mg%, and acceptable pulmonary condition (FEV and DLCO 
>50% of predicted) . Patients should be free of 
infections at the time of treatment. Patients should 
have a LVEF >50%. 
4.4 A serum creatinine less than 1.6 and an SGOT within 
the normal range is required. 
4.5 Patients must have an autologous bone marrow stored 
with 30% of the cells exposed to the LNL6 and the 
GINa retroviruses. Patients must sign an informed 
consent, must not be pregnant or lactating, and must 
be practicing adequate contraception if of 
childbearing potential. 
4.6 No patient who is unresponsive to platelet infusions 
will be eligible for this study. 
5 . 0 PRETREATMENT EVALUATION 
5.1 General: All patients should be registered with the 
data management office, Ext: 2-2926. Information 
pertaining to important patient characteristics will 
be recorded. 
5.2 Bone marrow aspiration and collection of peripheral 
blood stem cells and storage: Peripheral blood and 
marrow is to be stored. In vitro methods (CD34 
selection) for reducing the number of CLL cells will 
be used to reduce the level of CLL cells in the 
population of autologous marrow cells to be used for 
, transplant. Purged marrow cells collected following 
[396] 
Recombinant DNA Research, Volume 16 
